In Japanese and Chinese patients with mild to severe atopic dermatitis, crisaborole treatment was efficacious and well tolerated, says an article published in The Journal of Dermatology.
Atopic dermatitis is a chronic inflammatory skin illness that has a substantial influence on patients' and their families' general well-being. Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor that has been licensed in several countries for the treatment of mild-to-moderate atopic dermatitis. However, because a small fraction of the overall patient population in the pivotal trials was Asian, Lin Ma and colleagues undertook this study to investigate the safety and effectiveness of crisaborole in the Asian population with atopic dermatitis.

CrisADe CLEAR was a multicenter, randomized, double-blind, phase 3 research that looked at the effectiveness and safety of crisaborole ointment in Japanese and Chinese patients aged 2 years with mild-to-moderate atopic dermatitis affecting 5% of their treated body surface area. For 28 days, patients were randomly randomized to receive crisaborole or vehicle twice daily. At day 29, the primary outcome was the percentage change from baseline in the Eczema Area and Severity Index total score. Improvement and success on the Investigator's Static Global Assessment score at day 29 and change from baseline on the Peak Pruritus Numerical Rating Scale at week 4 were additional goals. The frequencies of treatment-emergent adverse events, major adverse events, and clinically significant alterations in vital signs and clinical laboratory indicators were used to assess safety.
The key findings of this study were:
1. At day 29, individuals treated with crisaborole had a substantially larger reduction in percentage change from baseline in Eczema Area and Severity Index total score compared to vehicle.
2. Those treated with crisaborole had significantly greater response rates for Investigator's Static Global Assessment improvement and success at day 29 than those treated with vehicle.
3. At week 4, crisaborole-treated patients had a considerably larger reduction in change from baseline on the Peak Pruritus Numerical Rating Scale than vehicle-treated patients (P = 0.0009). There were no new safety signals discovered.
In this research, crisaborole-treated patients outperformed vehicle-treated patients in all primary and significant secondary objectives, and no new safety concerns were discovered. Crisaborole was efficacious and well tolerated in Chinese and Japanese individuals with mild-to-moderate Alzheimer's disease aged 2 years.
Reference:
Ma, L., Zhang, L., Kobayashi, M., Tao, X., Qian, Q., Cheng, H., Liu, S., Zhou, Y., Chen, Y., & Zhang, J. (2023). Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild‐to‐moderate atopic dermatitis. In The Journal of Dermatology. Wiley. https://doi.org/10.1111/1346-8138.16792